JOINT AND MUSCLE RESEARCH INSITUTE
Clinical Research Study Opportunities; Exploring Safety and Effectiveness of New Treatments
Are you living with Lupus, Psoriatic Arthritis, Rheumatoid Arthritis, or Sjogren's Syndrome? We are conducting an exciting clinical research study aimed at testing innovative treatments that may help manage symptoms more effectively, with fewer side effects.
By joining our studies, you will have the opportunity to contribute to advancing medical research and potentially access cutting-edge treatments that could improve the quality of life for yourself and others living with these conditions.
Now Enrolling Studies
AbbVie-Protocol M23-699, Indication: Lupus
Title: SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE
Alumis-Protocol ESK-001-010
Title: A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patient with Systemic Lupus Erythematosus
Janssen-Protocol JNJ-77242113PSA3002
Title: A Phase 3, Multicenter, Randomized Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JAN-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis
Resolve-Protocol RSLV132-06
Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Intravenous RSLV-132 in Participants with Sjogren’s Syndrome (SS) with Moderate to Severe Symptom Burden
AbbVie-Protocol M23-700
Title: A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH)
Pending Studies
Janssen- Protocol JNJ-77242113PSA3001
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants with Active Psoriatic Arthritis